Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Gitlab Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Gitlab Inc trades at $52.47 (market cap $8.86B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 3.5× Gitlab Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GEHC | GTLB | |
|---|---|---|
Market Cap | $30.93B | $8.86B |
Volume | 5,033,451 | 6,160,270 |
Sector | Health | Technology |
52-Week High | $88.16 | $56.01 |
52-Week Low | $59.48 | $19.42 |
Enterprise Value | $39.39B | $7.60B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 62 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
GitLab (GTLB) trades at $51.95, down 7.25% today but maintains strong technical momentum with bullish moving averages. The company shows accelerating revenue growth, reaching $759M in 2025, with consistent earnings beats in recent quarters. Despite negative net margins, gross margins remain exceptional at 85.75%. Recent Q2 2026 results exceeded expectations, driving positive analyst sentiment and institutional interest.
Outlook remains positive with AI-driven demand and raised guidance, though high valuation multiples and persistent cash flow challenges present risks. Wall Street maintains a cautious 'Hold' consensus with $49.71 target, but recent earnings momentum suggests potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
